secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-106910
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio Q2 2025 net loss $25.8M; cash $119.6M; KRRO-110 interim data on track H2 2025
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $119.6M as of June 30, 2025, expected to fund operations into 2027.
- Net loss $25.8M for Q2 2025 vs $21.8M in Q2 2024; R&D expenses $21.0M (up from $17.1M).
- Collaboration revenue of $1.5M from Novo Nordisk partnership; zero collaboration revenue in prior year quarter.
- Phase 1/2a REWRITE trial of KRRO-110 for AATD: over 80% of planned healthy volunteers dosed; interim SAD readout expected H2 2025.
- KRRO-110 received EMA Orphan Drug Designation for AATD; rare metabolic disorder development candidate to be announced by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017025106910/0000950170-25-106910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017025106910/krro-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer